Norges Bank Invests $332.27 Million in IDEXX Laboratories, Inc. $IDXX

Norges Bank purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, Holdings Channel.com reports. The fund purchased 491,131 shares of the company’s stock, valued at approximately $332,265,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its position in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the period. Harbour Investments Inc. increased its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after acquiring an additional 16 shares during the period. CWA Asset Management Group LLC increased its position in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after acquiring an additional 17 shares during the period. Stratos Wealth Partners LTD. increased its position in IDEXX Laboratories by 1.7% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after acquiring an additional 18 shares during the period. Finally, Cary Street Partners Investment Advisory LLC increased its position in IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after acquiring an additional 18 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. Barclays dropped their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. BTIG Research dropped their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Trading Up 0.6%

Shares of IDXX stock opened at $566.79 on Tuesday. The business’s fifty day moving average price is $564.32 and its 200 day moving average price is $635.65. IDEXX Laboratories, Inc. has a 1-year low of $504.56 and a 1-year high of $769.98. The firm has a market capitalization of $44.71 billion, a PE ratio of 41.74, a P/E/G ratio of 3.27 and a beta of 1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.